Department of Biotechnology, Assam University, Silchar 788011, Assam, India.
Department of Biotechnology, Assam University, Silchar 788011, Assam, India.
Infect Genet Evol. 2020 Mar;78:104106. doi: 10.1016/j.meegid.2019.104106. Epub 2019 Nov 6.
Japanese encephalitis (JE) is a serious leading health complication emerging expansively that has severely affected the survival rate of human beings. This fatal disease is caused by JE Virus (JEV). The current study was carried out for designing a multi-epitope loaded peptide vaccine to prevent JEV. Based on reverse vaccinology and in silico approaches, octapeptide B-cell and hexapeptide T-cell epitopes belonging to five proteins, viz. E, prM, NS1, NS3 and NS5 of JEV were determined. Hydrophilicity, antigenicity, immunogenicity and aliphatic amino acids of the epitopes were estimated. Further, the epitopes were analyzed for different physicochemical parameters, e.g. total net charges, amino acid composition and Boman index. Out of all the epitopes, a total of four T-cell epitopes namely KRADSS, KRSRRS, SKRSRR and KECPDE and one B-cell epitope i.e. PKPCSKGD were found to have potential for raising immunity in human against the pathogen. Taking into account the outcome of this study, the pharmaceutical industries could initiate efforts to combine the identified epitopes together with adjuvant or carrier protein to develop a multi-epitope-loaded peptide vaccine against JEV. The peptide vaccine, being cost effective, could be administered as a prophylactic measure and in JEV infected individuals to combat the spread of this virus in human population. However, prior to administration into human beings, the vaccine must pass through several clinical trials.
日本脑炎 (JE) 是一种严重的主要健康并发症,正在广泛出现,严重影响了人类的生存率。这种致命的疾病是由日本脑炎病毒 (JEV) 引起的。本研究旨在设计一种多表位负载肽疫苗来预防 JEV。基于反向疫苗学和计算机方法,确定了属于 JEV 的五个蛋白(E、prM、NS1、NS3 和 NS5)的八肽 B 细胞和六肽 T 细胞表位。预测了表位的亲水性、抗原性、免疫原性和非极性氨基酸。此外,还对表位进行了不同理化参数的分析,例如总净电荷、氨基酸组成和 Boman 指数。在所有表位中,总共发现了四个 T 细胞表位,即 KRADSS、KRSRRS、SKRSRR 和 KECPDE,以及一个 B 细胞表位 PKPCSKGD,它们具有在人类中引发针对病原体的免疫的潜力。考虑到这项研究的结果,制药行业可以着手努力将鉴定出的表位与佐剂或载体蛋白结合起来,开发一种针对 JEV 的多表位负载肽疫苗。这种肽疫苗具有成本效益,可以作为预防措施和在 JEV 感染个体中使用,以阻止这种病毒在人类中的传播。然而,在给人类接种疫苗之前,疫苗必须经过多次临床试验。